Administration | Caveats and comments |
Uses and limitations | - Adequate response to a test dose is ideally established before use, but a patient with aVWS and acute bleeding may receive the first dose as a therapeutic trial.
- Do not use in children <2 years of age.
- Avoid or use with extreme care in individuals with cardiovascular disease.
- Avoid or use with extreme care in pregnant women.
|
Dosing | - May be repeated once daily for 3 to 5 days. Beyond 5 days, tachyphylaxis renders it ineffective.
|
Intravenous or subcutaneous | - Intravenous: 0.3 mcg/kg (maximum 20 mcg) diluted in 50 mL of normal saline and infused over 20 to 30 minutes.
- Subcutaneous (not approved for use in the United States): 0.3 mcg/kg (maximum 20 to 30 mcg) subcutaneously.
|
Nasal spray | - Use the formulation intended for hemostasis (concentration of 1.5 mg/mL; dose 150 mcg/spray), not the formulation for enuresis (concentration of 0.01%).
- Weight <50 kg: One spray in one nostril (total dose 150 mcg).
- Weight ≥50 kg: One spray in each nostril (total dose 300 mcg).
|
Adverse events |
Hyponatremia | - Avoid excess free water intake (oral or intravenous).
- Avoid NSAIDs.
- Monitor serum sodium.
|
Thrombotic events | - Especially of concern in individuals with pre-existing increased risk factors such as cardiovascular disease.
|
Headache, flushing, hypotension, hypertension | - Usually alleviated by slowing the infusion.
|